{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:41:26Z","timestamp":1760614886896,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":933,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.rmed.2010.07.009","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T05:05:20Z","timestamp":1281503120000},"page":"250-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive factors for evaluation of response to fluticasone propionate\/salmeterol combination in severe COPD"],"prefix":"10.1016","volume":"105","author":[{"given":"Andre-Bernard","family":"Tonnel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Tillie-Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Attali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zola","family":"Bavelele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lagrange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2010.07.009_bib1","unstructured":"Global initiative for chronic Obstructive Lung Disease (GOLD) executive summary. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. Updated 2008."},{"key":"10.1016\/j.rmed.2010.07.009_bib2","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1477-7525-3-56","article-title":"Health-related quality of life is related to COPD disease severity","volume":"3","author":"St\u00e5hl","year":"2005","journal-title":"Health Quality Life Outcomes"},{"key":"10.1016\/j.rmed.2010.07.009_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1164\/ajrccm.162.1.9909054","article-title":"Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease","volume":"162","author":"Taube","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.amjmed.2003.09.027","article-title":"Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity","volume":"116","author":"Sin","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1513\/pats.200601-002SF","article-title":"Improving dyspnea in chronic obstructive pulmonary disease, optimal treatment strategies","volume":"3","author":"Rabe","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2010.07.009_bib7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/thx.2004.037937","article-title":"Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD","volume":"60","author":"Aliverti","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2010.07.009_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1164\/ajrccm.153.3.8630581","article-title":"Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease","volume":"153","author":"Belman","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00003495-200060020-00005","article-title":"Long-acting beta 2 agonists in the management of stable chronic obstructive lung disease","volume":"60","author":"Cazzola","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2010.07.009_bib10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","article-title":"Efficacy of salmeterol xinafoate in the treatment of COPD","volume":"115","author":"Mahler","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.07.009_bib11","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Quality of life changes in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1183\/09031936.97.10040815","article-title":"An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)","volume":"10","author":"Boyd","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/thx.2004.033266","article-title":"Addition of salmeterol to existing treatment in patients with COPD: a 12 month study","volume":"61","author":"Stockley","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2010.07.009_bib14","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1164\/ajrccm.163.6.2009116","article-title":"Cellular and structural bases of chronic obstructive pulmonary disease","volume":"163","author":"Saetta","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000029466","article-title":"Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease","volume":"67","author":"Yildiz","year":"2000","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2010.07.009_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1183\/09031936.02.00301302","article-title":"Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice","volume":"20","author":"Soriano","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(97)03471-5","article-title":"Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease","volume":"351","author":"Paggiaro","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2010.07.009_bib18","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.rmed.2010.07.009_bib19","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1185\/030079904X3708","article-title":"The place of inhaled corticosteroids in chronic obstructive pulmonary disease","volume":"20","author":"Selroos","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rmed.2010.07.009_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1378\/chest.126.1.220","article-title":"Inhaled combination therapy with long-acting \u00df2-agonists and corticosteroids in stable COPD","volume":"126","author":"Cazzola","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.07.009_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2010.07.009_bib22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/rccm.200508-1321OC","article-title":"Antiinflammatory effects of salmeterol\/fluticasone propionate in chronic obstructive lung disease","volume":"173","author":"Barnes","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1183\/09031936.04.00072703","article-title":"Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease","volume":"24","author":"O\u2019Donnell","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1378\/chest.130.3.647","article-title":"Effect of fluticasone propionate\/salmeterol on lung hyperinflation and exercise endurance in COPD","volume":"130","author":"O\u2019Donnell","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.07.009_bib25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe COPD","volume":"175","author":"Kardos","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib26","first-page":"43","article-title":"Validation of the St George\u2019s questionnaire for measuring the quality of life in patients with chronic obstructive pulmonary disease","volume":"13","author":"Bouchet","year":"1996","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmed.2010.07.009_bib27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1513\/pats.200511-118SF","article-title":"Approaches to improving health status in chronic obstructive pulmonary disease: one or several?","volume":"3","author":"Wouters","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2010.07.009_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1513\/pats.200504-036SR","article-title":"Chronic obstructive pulmonary disease outcome measurements: what\u2019s important? What\u2019s useful?","volume":"2","author":"Gross","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2010.07.009_bib29","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1378\/chest.121.4.1042","article-title":"Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation","volume":"121","author":"Newton","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.07.009_bib30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/thorax.58.8.659","article-title":"For the ISOLDE study investigators. Bronchodilator reversibility testing in chronic obstructive respiratory disease","volume":"58","author":"Calverley","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2010.07.009_bib31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/thorax.58.8.647","article-title":"Responses to steroids and bronchodilators in COPD in the ISOLDE trial: the fat lady sings on (editorial)","volume":"58","author":"Gross","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2010.07.009_bib32","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.123.5.1441","article-title":"Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses","volume":"123","author":"Tashkin","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.07.009_bib33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/thorax.58.8.654","article-title":"Prednisolone response in patients with chronic obstructive disease: results from the ISOLDE study","volume":"58","author":"Burge","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2010.07.009_bib34","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1164\/ajrccm.164.5.2012122","article-title":"Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease","volume":"164","author":"O\u2019Donnell","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1034\/j.1399-3003.2000.16b14.x","article-title":"Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest","volume":"16","author":"Diaz","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1164\/rccm.200407-867OC","article-title":"Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease","volume":"171","author":"Casanova","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1513\/pats.200508-084SF","article-title":"Dynamic hyperinflation: is it worth measuring?","volume":"3","author":"Calverley","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2010.07.009_bib38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1513\/pats.200508-093DO","article-title":"Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease","volume":"3","author":"O\u2019Donnell","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2010.07.009_bib39","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/thorax.56.11.880","article-title":"Health status measurement in chronic obstructive pulmonary disease","volume":"56","author":"Jones","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2010.07.009_bib40","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1183\/09031936.06.00130605","article-title":"Predictors of success and failure in pulmonary rehabilitation","volume":"27","author":"Garrod","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib41","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.rmed.2005.03.019","article-title":"Proposal for a multidimensional staging system for chronic obstructive pulmonary disease","volume":"99","author":"Celli","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1183\/09031936.05.00045505","article-title":"Pulmonary rehabilitation and the BODE index in COPD","volume":"26","author":"Cote","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"Jones","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib44","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.rmed.2005.08.017","article-title":"Reference values and repeatability of inspiratory capacity for men and women aged 65\u201385","volume":"100","author":"Tantucci","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib45","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250\u00a0\u03bcg)\/salmeterol (50\u00a0\u03bcg) combined in the Diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.07.009_bib46","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus\u2122 device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.07.009_bib47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1513\/pats.200603-096SS","article-title":"Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease","volume":"3","author":"Sin","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2010.07.009_bib48","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1183\/09031936.04.00116004","article-title":"Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD","volume":"23","author":"O\u2019Donnell","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1183\/09031936.03.00020102","article-title":"Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD","volume":"21","author":"Di Marco","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.07.009_bib50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1513\/pats.200512-126SF","article-title":"Health status: what does it mean for payers and patients?","volume":"3","author":"Jones","year":"2006","journal-title":"Proc Am Thorac Soc"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611110003288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611110003288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:07:05Z","timestamp":1760612825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611110003288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0954611110003288"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2010.07.009","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors for evaluation of response to fluticasone propionate\/salmeterol combination in severe COPD","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2010.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}